
Navigo Proteins Successfully Develops Affinity Resin against Ferritin for blood fraction processing

*Affinity resin enables efficient capture of Ferritin from blood fractions
despite low serum concentrations*

Halle/Saale, Germany, July 20th, 2022. Navigo Proteins GmbH (“Navigo”), a premier protein engineering company and developer of affinity ligands for custom chromatography solutions, today announces successful development of a Precision Capturing® affinity resin for the capture of Ferritin. This primarily intracellular protein is released into the blood stream in small amounts where it acts as an iron carrier. PreviPharma, a company focusing on the therapeutic potential of plasma derived proteins used in novel therapeutics, identified Ferritin as a protein of interest. Due to the very low naturally occurring quantities of Ferritin in fractionated blood plasma it is a challenge to make it a viable source for therapeutic development. Currently, Ferritin ends up as part of the waste of the blood fractionation industry. Only around 16 out of approximately 10.000 proteins available in plasma have been developed for therapeutic use so far, in part due to unviable purification processes or identification of therapeutic uses. The new affinity chromatography option now efficiently captures even trace elements of Ferritin from those waste fractions opening up exciting development opportunities for the iron carrier protein and outlining a clear path for the accessibility of other plasma proteins for commercial development in the future.

Florian Settele, Head of Business Unit Precision Capturing said: “The Precision Capturing® technology has once again proven its capabilities in the field of protein purification. Affinity allows for the economic purification of even highly diluted targets of interest and facilitates new possibilities for protein therapeutics from recombinant as well as non-recombinant sources. We are delighted to provide this solution to PreviPharma who pushes forward the field of protein therapeutics and strive to innovate, especially, for patients with an unmet medical need.”

Tina Berger, Senior Scientist and Project Manager said: “PreviPharma has been impressed by Navigo’s customer and technology focus and the speed that Navigo has been able to develop research grade affinity resins. The science and the quality of delivered materials as well as the potential to further develop ligands for commercial purposes including membrane bound ligands is outstanding.”

About Navigo Proteins GmbH

Navigo Proteins is a premier protein engineering company, specialized in creating novel affinity ligands for custom affinity purification of complex biologics (PRECISION CAPTURING®) and as ligands in biotherapeutic drug candidates (PRECISION TARGETING). Navigo’s unique protein engineering expertise is based on the company’s proprietary platform of different small and stable, yet highly engineerable scaffold proteins. Navigo’s PRECISION CAPTURING® unit creates affinity ligands and chromatography resins that specifically bind and purify biologics, even without Fc part

and notably enable platformized one-step downstream processes. PRECISION CAPTURING® is based on an artificial Protein A scaffold ('Precision X'), combining the downstream processing industry-accepted virtues of Protein A with novel selectivities and mild elution conditions. PRECISION CAPTURING® is applicable for purifying recombinant proteins, monoclonal antibodies, viruses, VLPs and other biologics. Navigo works with renowned global partners to convert its affinity ligands into ready-to-use, GMP-compliant affinity resins for large-scale, commercial biologics downstream processing.

For more information visit www.navigo-proteins.com or follow us on LinkedIn.

About PreviPharma

PreviPharma focuses on the therapeutic potential of plasma proteins used in novel therapeutic areas in addition to genetic disorder substitution therapies. Plasma protein market including recombinant proteins has grown to more than \$ 24 billion of annual sales. However, only around 16 out of approximately 10.000 plasma proteins are presently available for therapeutic use. Significant potential for new drugs based on the so far unused proteins is left untapped. PreviPharma's Medical Innovation Platform (MIP) includes candidates focusing on various therapeutic areas such as neurology, cardiovascular diseases, hematology or infectious diseases. PreviPharma is constantly improving its data generation for its proprietary MIP candidates to become exceptional new drug candidates.

For more information visit www.previpharma.com or follow us on LinkedIn.

Navigo Contact:

Laura Müller
Business Development Manager
+49 (0)345 27996337
BD@navigo-proteins.com

PreviPharma Contact:

Tina Berger
Senior Scientist and Project Manager
+49 (0) 621 72847848
info@previpharma.com